Mibispect (Copper Tetramibi Tetrafluoroborate)

The compound combines copper ions with a tetramibi moiety. Copper can disrupt microbial enzyme systems and generate oxidative stress, while the tetramibi component may interfere with nucleic acid synthesis. Together, these actions can inhibit the growth of susceptible microorganisms.

The dosing regimen for Mibispect is determined by the treating physician based on the specific investigational protocol, patient characteristics, and clinical response. No standardized dose is publicly established.

Safety data for Copper Tetramibi Tetrafluoroborate in pregnancy or lactation are limited. It should be avoided unless the potential therapeutic benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and any required import documentation.

Mibispect’s copper‑tetramibi complex is distinct from simpler copper salts or other copper‑based agents, offering a combined metal‑ion and organic moiety that may provide broader antimicrobial activity. However, comparative clinical data are limited, and efficacy must be evaluated within the context of each specific study.

Mibispect should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the product. Before administration, allow the solution to reach room temperature if required, and inspect for particulate matter.

Mibispect is supplied as an intravenous solution and must be administered by a qualified healthcare professional. The infusion rate and duration are defined by the clinical protocol, and patients should be monitored for infusion‑related reactions throughout the administration.

Serious risks include severe hypersensitivity reactions such as anaphylaxis, acute renal failure, significant hepatic injury, copper overload leading to neurotoxicity, and hemolytic anemia. Prompt recognition and management of these events are essential.

Mibispect should not be given to individuals with known hypersensitivity to copper compounds, existing severe renal or hepatic impairment, or those who are pregnant or breastfeeding unless the potential benefit outweighs the risk. It is also contraindicated in patients receiving high‑dose copper supplements or strong chelating agents.